Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DK87UQ
|
|||
| Drug Name |
PF-07062119
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Guanylyl cyclase C (GUCY2C) | Target Info | Inhibitor | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04171141) Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.. U.S. National Institutes of Health. | |||
| REF 2 | Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.